Literature DB >> 1747764

Cytokine-induced activation of the neuroendocrine stress axis persists in endotoxin-tolerant mice.

I N Mefford1, C F Masters, M P Heyes, R L Eskay.   

Abstract

Chronic administration of lipopolysaccharide (LPS) to mice markedly reduced activation of the neuroendocrine stress axis elicited by an acute challenge dose of LPS. LPS-induced elevation in norepinephrine turnover in the hypothalamus showed complete tolerance whereas elevation of plasma corticosterone showed only partial tolerance. Challenge-induced increased turnover of dopamine in hypothalamus persisted in LPS-tolerant animals. Neuroendocrine activation persisted following acute challenge with interleukin-1 and tumor necrosis factor following chronic LPS exposure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1747764     DOI: 10.1016/0006-8993(91)90154-n

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

1.  Independent down-regulation of central and peripheral tumor necrosis factor production as a result of lipopolysaccharide tolerance in mice.

Authors:  R Faggioni; G Fantuzzi; P Villa; W Buurman; L J van Tits; P Ghezzi
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

2.  Alteration of the physiological responses to indomethacin by endotoxin tolerance in the rat: a possible role for central vasopressin.

Authors:  M F Wilkinson; Q J Pittman
Journal:  J Physiol       Date:  1994-09-15       Impact factor: 5.182

3.  Intracerebroventricular injection of anti-Fas activates the hypothalamus-pituitary-adrenal axis and induces peripheral interleukin-6 and serum amyloid A in mice: comparison with other ligands of the tumor necrosis factor/nerve growth factor receptor superfamily.

Authors:  F Benigni; S Sacco; L Aloe; P Ghezzi
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

4.  Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases.

Authors:  G Fantuzzi; P Ghezzi
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.